Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Vaxcyte, Inc. (PCVX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$65.68+8.01%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for PCVX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
4 published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Reduce losses and move toward positive earnings | A primary condition in Vaxcyte, Inc.'s published investment case. The stated target is EPS loss narrows from -8.48 in 2026 to less negative in 2027. | Intact | EPS loss worsens or stays flat beyond 2027 | Diluted EPS: $-1.99 per share FY2026-Q3; GAAP. Published target: EPS loss narrows from -8.48 in 2026 to less negative in 2027. Annual target cannot be compared with a quarterly or TTM observation. Nov 4, 2026-1.99 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a clinical-stage healthcare growth story, not an established earnings compounder. The long-term thesis is in a watch state: key studies are progressing, but recent financial performance is weak and confidence in the overall evidence snapshot is low.
The snapshot provides no valuation comparison or clear account of market expectations, so whether PCVX is cheap, fair, or expensive versus peers is unclear. It also reports low pricing fragility, but that alone does not show what clinical or business success the market already assumes.
Near term, results may remain uneven: the company is loss-making, recent performance is weak, and the snapshot flags elevated risk of another earnings miss. Over the multi-year view, VAX-31 data and progress in the VAX-A1 study are central, while the cash balance has declined but remains substantial for supporting development.
The key swing factor is whether VAX-31 OPUS data support the planned path toward a biologics license application; OPUS-1 topline data were announced on October 5, 2026, with OPUS-2 and OPUS-3 data expected in the first half of 2027. The thesis also depends on VAX-A1 progress, cash use, and whether management avoids a guidance cut; the snapshot's wider sector signals are mixed, with a healthcare tailwind alongside weaker jobs data that could raise recession concerns.
For the next 1 to 3 years, PCVX remains a clinical-milestone story with meaningful uncertainty, weak recent performance, and important upcoming data. The long-term thesis depends more on study outcomes and execution than on current earnings. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Successful execution of manufacturing agreement with Thermo Fisher | The company has a new manufacturing deal with Thermo Fisher. | Intact | Manufacturing delays or failure to meet milestones in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Generate initial vaccine revenue | A primary condition in Vaxcyte, Inc.'s published investment case. The stated target is Revenue reaches at least $87 million in 2027. | Intact | Revenue fails to grow or remains near zero by 2027 | Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue reaches at least $87 million in 2027. Annual target cannot be compared with a quarterly or TTM observation. Aug 5, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Complete Phase 3 VAX-31 trial enrollment and progress to next steps | Enrollment for the Phase 3 VAX-31 trial is complete. | Intact | Trial enrollment or advancement stalls or reverses in 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-6.69 → $-6.50 · observed estimates
$0.09B → $0.09B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-6.69 | $87,145,778 | 6 / 9 |
| 2026-07-25 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-07-26 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-07-27 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-07-28 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-07-29 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-07-30 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-07-31 | $-6.69 | $87,145,778 | 6 / 9 |
| 2026-08-01 | $-6.69 | $87,145,778 | 6 / 9 |
| 2026-08-02 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-08-03 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-08-04 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-08-05 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-08-06 | $-7.42 | $87,145,780 | 7 / 9 |
| 2026-08-07 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-08 | $-7.20 | $41,075,000 | 7 / 4 |
| 2026-08-09 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-10 | $-7.20 | $41,075,000 | 7 / 4 |
| 2026-08-12 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-13 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-14 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-15 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-16 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-17 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-18 | $-6.63 | $87,145,778 | 6 / 9 |
| 2026-08-19 | $-6.63 | $87,145,778 | 6 / 8 |
| 2026-08-20 | $-6.52 | $87,145,778 | 6 / 8 |
| 2026-08-21 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-22 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-23 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-24 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-25 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-26 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-27 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-28 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-29 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-30 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-08-31 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-01 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-02 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-03 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-04 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-05 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-06 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-07 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-08 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-09 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-10 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-11 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-12 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-13 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-14 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-15 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-16 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-17 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-18 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-19 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-20 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-21 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-22 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-23 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-24 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-25 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-26 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-27 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-28 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-29 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-09-30 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-10-01 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-10-02 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-10-03 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-10-04 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-10-05 | $-6.52 | $87,145,778 | 6 / 9 |
| 2026-10-06 | $-6.58 | $87,145,778 | 6 / 9 |
| 2026-10-07 | $-6.73 | $98,039,000 | 5 / 9 |
| 2026-10-08 | $-6.58 | $87,145,778 | 5 / 9 |
| 2026-10-09 | $-6.56 | $87,145,778 | 6 / 9 |
| 2026-10-10 | $-6.56 | $87,145,778 | 6 / 9 |
| 2026-10-11 | $-6.56 | $87,145,778 | 6 / 9 |
| 2026-10-12 | $-6.56 | $87,145,778 | 6 / 9 |
| 2026-10-13 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-14 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-15 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-16 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-17 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-18 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-19 | $-6.46 | $87,145,778 | 6 / 9 |
| 2026-10-20 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-21 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-22 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-23 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-24 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-25 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-26 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-27 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-28 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-29 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-30 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-10-31 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-11-01 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-11-02 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-11-03 | $-6.50 | $87,145,778 | 6 / 9 |
| 2026-11-04 | $-6.50 | $87,145,778 | 6 / 9 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
Next earnings date unavailable
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earnings4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.